Table 1 Baseline participant characteristics.
Healthy Control (n = 19) | IPF (n = 17) | dcSSc ILD(n = 16) | dcSSc No ILD (n = 11) | lcSSc ILD (n = 23) | lcSSc No ILD (n = 18) | p-value | |
|---|---|---|---|---|---|---|---|
Age | 51 ± 19 | 73 ± 7 | 52 ± 14 | 54 ± 14 | 58 ± 11 | 58 ± 10 | < 0.0001 |
Male Count (%) | 6 (32%) | 12 (71%) | 8 (50%) | 3 (27%) | 4 (17%) | 1 (6%) | |
Disease duration | NA | 1.8 ± 2.1 | 3.6 ± 5.1 | 7.6 ± 10.2 | 7.9 ± 8.7 | 11.6 ± 7.1 | < 0.0001 |
Ever smoker (%) | 3 (16) | 14 (82) | 8 (50) | 4 (36) | 12 (52) | 6 (33) | 0.0020 |
Pack years [range] | 0[0, 1] | 22[0, 90] | 5[0,30] | 4[0, 38] | 12[0,51] | 6[0,40] | 0.0003 |
Baseline FVC % (sample size) | NA | 85 ± 20 (17) | 75 ± 17 (12) | 113 ± 7 (3) | 83 ± 25 (16) | 88 ± 7 (2) | 0.0753 |
Baseline DLCO % (sample size) | NA | 49 ± 11 (13) | 49 ± 12 (12) | 79 ± 12 (3) | 50 ± 19 (16) | 63 ± 3 (2) | 0.0588 |
Antifibrotic Treatment (%) | 0 (0%) | 7 (41%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | < 0.0001 |
Immunosuppressive Treatment (%) | 0 (0%) | 0 (0%) | 6 (38%) | 1 (10%) | 9 (39%) | 0 (0%) | 0.0003 |
Annualized FVC % Change (sample size) | NA | − 6.2 ± 13.6 (17) | − 3.1 ± 9.2 (14) | − 0.2 ± 4.4 (3) | − 1.0 ± 7.6 (20) | NA | 0.1365 |
Annualized DLCO % Change (sample size) | NA | − 7.8 ± 18.6 (14) | − 1.2 ± 5.5 (10) | 0.8 ± 3.2 (3) | − 0.4 ± 6.8 (14) | NA | 0.5252 |
